Shinozaki N - Search Results

1

The Pluripotent Stem-Cell Marker Alkaline Phosphatase is Highly Expressed in Refractory Glioblastoma with DNA Hypomethylation.

Iwadate Y, Suganami A, Tamura Y, Matsutani T, Hirono S, Shinozaki N, Hiwasa T, Takiguchi M, Saeki N. Iwadate Y, et al. Among authors: shinozaki n. Neurosurgery. 2017 Feb 1;80(2):248-256. doi: 10.1093/neuros/nyw026. Neurosurgery. 2017. PMID: 28173571

2

Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.

Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, Iwadate Y. Shinozaki N, et al. J Neurosurg. 2011 Jun;114(6):1640-7. doi: 10.3171/2010.11.JNS10553. Epub 2011 Jan 7. J Neurosurg. 2011. PMID: 21214332

3

Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.

Iwadate Y, Shinozaki N, Matsutani T, Uchino Y, Saeki N. Iwadate Y, et al. Among authors: shinozaki n. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1016-21. doi: 10.1136/jnnp-2015-311516. Epub 2016 Feb 4. J Neurol Neurosurg Psychiatry. 2016. PMID: 26848169 Free PMC article.

4

Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma.

Iwadate Y, Matsutani T, Hirono S, Shinozaki N, Saeki N. Iwadate Y, et al. Among authors: shinozaki n. J Neurooncol. 2016 Aug;129(1):101-7. doi: 10.1007/s11060-016-2145-6. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193555

5

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N. Iwadate Y, et al. Among authors: shinozaki n. J Neurooncol. 2011 May;102(3):443-9. doi: 10.1007/s11060-010-0340-4. Epub 2010 Aug 19. J Neurooncol. 2011. PMID: 20721680

6

Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.

Iwadate Y, Matsutani T, Shinozaki N, Saeki N. Iwadate Y, et al. Among authors: shinozaki n. Anticancer Res. 2011 Dec;31(12):4475-9. Anticancer Res. 2011. PMID: 22199318

7

Selection of chemotherapy for glioblastoma expressing O(6)-methylguanine-DNA methyltransferase.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Oide T, Tanizawa T, Nakatani Y, Saeki N, Fujimoto S. Iwadate Y, et al. Among authors: shinozaki n. Exp Ther Med. 2010 Jan;1(1):53-57. doi: 10.3892/etm_00000009. Epub 2010 Jan 1. Exp Ther Med. 2010. PMID: 23136592 Free PMC article.

8

Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.

Iwadate Y, Suganami A, Ikegami S, Shinozaki N, Matsutani T, Tamura Y, Saeki N, Yamanaka R. Iwadate Y, et al. Among authors: shinozaki n. J Neurooncol. 2014 Apr;117(2):261-8. doi: 10.1007/s11060-014-1379-4. Epub 2014 Feb 1. J Neurooncol. 2014. PMID: 24488444

9

Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas.

Adachi-Hayama M, Adachi A, Shinozaki N, Matsutani T, Hiwasa T, Takiguchi M, Saeki N, Iwadate Y. Adachi-Hayama M, et al. Among authors: shinozaki n. BMC Cancer. 2014 Jun 18;14:452. doi: 10.1186/1471-2407-14-452. BMC Cancer. 2014. PMID: 24946857 Free PMC article.

10

IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.

Iwadate Y, Matsutani T, Hirono S, Ikegami S, Shinozaki N, Saeki N. Iwadate Y, et al. Among authors: shinozaki n. J Neurooncol. 2015 Sep;124(3):493-500. doi: 10.1007/s11060-015-1863-5. Epub 2015 Aug 5. J Neurooncol. 2015. PMID: 26243269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters